Weighing in on GLP-1 drugs

When it comes to GLP-1 drugs like Ozempic, Wegovy, and Mounjaro there’s a lot to talk about, from the science behind the drugs and where it could go next to the cultural and societal implications of this highly effective treatment for diabetes, weight loss, and potentially much more.

On today’s podcast editor-in-chief Jonah Comstock and Deep Dive editor Eloise McLennan forego the usual interview format for an editor-to-editor discussion of a wide variety of topics around GLP-1s.

The conversation touches on the stigma surrounding obesity and the ways in which GLP-1s are and aren’t reshaping the age-old narratives around obesity and weight loss. The two also examine the challenges of patient adherence, the rise of the grey market, and the ethical considerations of off-label prescribing, as well as what oral formations and new treatment areas could mean for the evolutions of the space.

Tune in for a broad-ranging discussion of one of the most important breakthrough medicines of the decade.